Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018071500 - ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF

Publication Number WO/2018/071500
Publication Date 19.04.2018
International Application No. PCT/US2017/056078
International Filing Date 11.10.2017
IPC
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 47/6873
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6873the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 2317/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applicants
  • AGENUS INC. [US]/[US]
Inventors
  • WILSON, Nicholas Stuart
  • SAVITSKY, David Adam
  • JENNINGS, Shawn Michael
  • VAN DIJK, Marc
  • MUNDT, Cornelia Anne
Agents
  • WILKINS, Andrew T.
  • ALTER, Scott
  • ANIS, Hissan
  • BARONE, Stephen B.
  • BARTON, Steven K.
  • CHAPMAN, Gary B.
  • CHEN, Xiaoyue (Peter
  • COUGHLIN, Sean M.
  • CURTIS, Michael J.
  • CUSTER, Andrew W.
  • DECONTI, Giulio A.
  • DELANEY, Marie
  • DIZEREGA, Philip
  • DZURELLA, Palmer
  • JEFFRIES, James H.
  • JOHNSON, Joseph
  • KNAPP, Jacquelyn D.
  • LAMBRECHTS, Robert J.
  • LINK, Douglas
  • MACK, Brian R.
  • POPLIN, Alan J.
  • QUINN, Anna
  • SENDEK, Timothy
  • SMITH, Mary Breen
  • SPELLBERG, Michael
  • STEELE, Alan
  • STERNSTEIN, Allan
  • STONE-HULSLANDER, Judith
  • SULLIVAN, Sally A.
  • TEOFILO, Javier
  • TREMBATH, Jon
  • TRINQUE, Brian C.
  • VELEMA, James H.
  • VOCK, Curtis A.
  • WASHINGTON, Michele
  • XU, Lily
Priority Data
62/406,76611.10.2016US
62/420,28010.11.2016US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
(FR) ANTICORPS ANTI-LAG-3 ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN) The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
(FR) La présente invention concerne des anticorps qui se lient spécifiquement à LAG-3 (par exemple, LAG-3 humain) et qui ont un effet antagoniste sur la fonction LAG-3. L'invention concerne également des compositions pharmaceutiques comprenant ces anticorps, des acides nucléiques codant pour ces anticorps, des vecteurs d'expression et des cellules hôtes permettant de fabriquer ces anticorps, et des procédés de traitement d'un sujet à l'aide de ces anticorps.
Related patent documents
SG11201902016VThis application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
UAa201904900This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau